Intimal hyperplasia following vascular injury is not inhibited by an antisense thrombin receptor oligodeoxynucleotide
Research article published in Journal of cellular physiology (1997)
Abstract
Thrombin is a multifunctional serine protease with central functions in hemostasis, but demonstration of its role in the initiation and maintenance of cell proliferation which occurs following vascular injury is still lacking. To determine the role played by thrombin and its receptor in neointimal accumulation of smooth muscle cells in a rabbit carotid artery model, we have used an 18 mer antisense phosphorothioate oligonucleotide (ODN) directed against the translation initiation region of the human thrombin receptor gene. The antisense ODN inhibited in a dose-dependent manner thrombin- or thrombin receptor activating peptide-induced human aortic smooth muscle cell proliferation. The growth-inhibitory effect of thrombin receptor antisense ODN was preventable by an excess of sense oligomer and specific for thrombin. The suppression of growth was accompanied by a marked decrease of the level of thrombin receptor expression as evidenced by [125I]-thrombin binding to smooth muscle cells. Under the same experimental conditions, the corresponding sense ODN was inactive. The effect of the antisense ODN on intimal smooth muscle hyperplasia in rabbit carotid arteries subjected to endothelial injury was then investigated. The topical application of the antisense (500 microg/artery) but not the sense ODN dissolved in F127 pluronic gel around the injured artery resulted, 2 weeks after the application, in a dramatic reduction of the expression of the thrombin receptor mRNA and protein levels as determined by in situ hybridization and immunohistochemistry. However, intimal smooth muscle cell accumulation as estimated by an intimal to medial cross-sectional area ratio was reduced only by 2.7% (vs. 10.3% for the sense ODN), whereas r-hirudin (200 microg/kg/day, s.c.), a potent direct thrombin inhibitor significantly reduced the formation of neointima in denuded carotid arteries (35.4% inhibition, P = 0.03).
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Intimal hyperplasia following vascular injury is not inhibited by an antisense thrombin receptor oligodeoxynucleotide.
Por qué esto importa para la hirudoterapia
Este estudio evaluó si un oligonucleótido antisense fosforotioato de 18 mer (ODN) dirigido contra el gen del receptor de trombina humana podía prevenir la hiperplasia del músculo liso intimal tras lesión endotelial carotídea en conejos, incluyéndose hirudina recombinante (200 µg/kg/día, s.c.) como comparación. El ODN antisense redujo la expresión de ARNm y proteína del receptor de trombina, pero la relación íntima-media solo se redujo en un 2,7% frente al 10,3% del control sentido; en contraste, la r-hirudina redujo significativamente la formación de neointima (35,4% de inhibición, P = 0,03). El resumen describe la r-hirudina únicamente como un «potente inhibidor directo de la trombina» sin identificarla como derivada de la sanguijuela, por lo que su conexión con la ASH o la hirudoterapia es inferible más que explícita; además, el trabajo es un estudio en modelo animal de un agente recombinante aislado, no de terapia con sanguijuela viva.
Citación
Intimal hyperplasia following vascular injury is not inhibited by an antisense thrombin receptor oligodeoxynucleotide
Herbert JM et al. · Journal of cellular physiology, 1997
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026